News articles about Hospira (NYSE:HSP) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Hospira earned a media sentiment score of 0.17 on Accern’s scale. Accern also assigned news articles about the healthcare company an impact score of 46.0330331528394 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Shares of NYSE HSP remained flat at $$89.96 during trading on Friday.
ILLEGAL ACTIVITY WARNING: “Hospira (HSP) Receiving Somewhat Positive Press Coverage, Report Shows” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/04/15/hospira-hsp-receiving-somewhat-positive-press-coverage-report-shows.html.
Hospira Company Profile
Hospira, Inc provides injectable pharmaceutical drugs and infusion technologies and it develops, manufactures, distributes and markets biosimilars. The Company’s portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products.
Receive News & Ratings for Hospira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hospira and related companies with MarketBeat.com's FREE daily email newsletter.